Presenting features and treatment failure according to CD20 expression
Presenting feature . | CD20-, no. (%) . | CD20+, no. (%) . | P . |
|---|---|---|---|
| Age, y | .001 | ||
| Younger than 1 | 14 (93) | 1 (7) | |
| 1-10 | 121 (48) | 131 (52) | |
| Older than 10 | 49 (57) | 37 (43) | |
| WBC count, × 109/L | .85 | ||
| Less than 50 | 142 (52) | 129 (48) | |
| 50 or greater | 42 (51) | 40 (49) | |
| Sex | .33 | ||
| Male | 101 (55) | 84 (45) | |
| Female | 83 (49) | 85 (51) | |
| Race | .02 | ||
| White | 150 (55) | 122 (45) | |
| African American | 17 (34) | 33 (66) | |
| Other | 17 (55) | 14 (45) | |
| Liver size | .001 | ||
| 5 cm or larger | 35 (38) | 58 (62) | |
| Less than 5 cm | 149 (57) | 111 (43) | |
| Spleen size | .02 | ||
| 5 cm or larger | 38 (42) | 53 (58) | |
| Less than 5 cm | 146 (56) | 116 (44) | |
| DNA index | .07 | ||
| 1.16 or greater | 36 (43) | 47 (57) | |
| Less than 1.16 | 148 (55) | 122 (45) | |
| Ploidy subgroup | .58‡ | ||
| Diploid | 25 (60) | 17 (40) | |
| Hypodiploid | 9 (39) | 14 (61) | |
| Pseudodiploid | 63 (53) | 56 (47) | |
| Hyper 47-50 | 29 (51) | 28 (49) | |
| Hyper over 51 | 49 (49) | 51 (51) | |
| NA | 9 (75) | 3 (25) | |
| MLL-AF4 | < .001 | ||
| MLL-AF4+ | 14 (100) | 0 (0) | |
| MLL-AF4- | 170 (50) | 169 (50) | |
| BCR-ABL | .07 | ||
| BCR-ABL+ | 4 (29) | 10 (71) | |
| BCR-ABL- | 180 (53) | 159 (47) | |
| E2A-PBX | .67 | ||
| E2A-PBX+ | 9 (47) | 10 (53) | |
| E2A-PBX | 175 (52) | 159 (48) | |
| TEL-AML1 | .66‡ | ||
| TEL-AML1+ | 48 (57) | 36 (43) | |
| TEL-AML1- | 113 (54) | 95 (46) | |
| TEL-AML1 NA | 23 (38) | 38 (62) | |
| Treatment failure* | 34 (64) | 19 (37) | .05 |
| Induction failure | 5 (71) | 2 (29) | |
| Isolated BM relapse | 21 (68) | 10 (32) | |
| Other† | 8 (53) | 7 (47) |
Presenting feature . | CD20-, no. (%) . | CD20+, no. (%) . | P . |
|---|---|---|---|
| Age, y | .001 | ||
| Younger than 1 | 14 (93) | 1 (7) | |
| 1-10 | 121 (48) | 131 (52) | |
| Older than 10 | 49 (57) | 37 (43) | |
| WBC count, × 109/L | .85 | ||
| Less than 50 | 142 (52) | 129 (48) | |
| 50 or greater | 42 (51) | 40 (49) | |
| Sex | .33 | ||
| Male | 101 (55) | 84 (45) | |
| Female | 83 (49) | 85 (51) | |
| Race | .02 | ||
| White | 150 (55) | 122 (45) | |
| African American | 17 (34) | 33 (66) | |
| Other | 17 (55) | 14 (45) | |
| Liver size | .001 | ||
| 5 cm or larger | 35 (38) | 58 (62) | |
| Less than 5 cm | 149 (57) | 111 (43) | |
| Spleen size | .02 | ||
| 5 cm or larger | 38 (42) | 53 (58) | |
| Less than 5 cm | 146 (56) | 116 (44) | |
| DNA index | .07 | ||
| 1.16 or greater | 36 (43) | 47 (57) | |
| Less than 1.16 | 148 (55) | 122 (45) | |
| Ploidy subgroup | .58‡ | ||
| Diploid | 25 (60) | 17 (40) | |
| Hypodiploid | 9 (39) | 14 (61) | |
| Pseudodiploid | 63 (53) | 56 (47) | |
| Hyper 47-50 | 29 (51) | 28 (49) | |
| Hyper over 51 | 49 (49) | 51 (51) | |
| NA | 9 (75) | 3 (25) | |
| MLL-AF4 | < .001 | ||
| MLL-AF4+ | 14 (100) | 0 (0) | |
| MLL-AF4- | 170 (50) | 169 (50) | |
| BCR-ABL | .07 | ||
| BCR-ABL+ | 4 (29) | 10 (71) | |
| BCR-ABL- | 180 (53) | 159 (47) | |
| E2A-PBX | .67 | ||
| E2A-PBX+ | 9 (47) | 10 (53) | |
| E2A-PBX | 175 (52) | 159 (48) | |
| TEL-AML1 | .66‡ | ||
| TEL-AML1+ | 48 (57) | 36 (43) | |
| TEL-AML1- | 113 (54) | 95 (46) | |
| TEL-AML1 NA | 23 (38) | 38 (62) | |
| Treatment failure* | 34 (64) | 19 (37) | .05 |
| Induction failure | 5 (71) | 2 (29) | |
| Isolated BM relapse | 21 (68) | 10 (32) | |
| Other† | 8 (53) | 7 (47) |